Diagnostics Q2 revenue rises slightly amid international expansion

Co-Diagnostics

13/08/2026 21:10

Overview
US molecular diagnostics firm Q2 revenue rose slightly yr/yr on higher product sales
Net loss for Q2 narrowed from prior year as operating expenses declined
Company advanced FDA submission and expanded manufacturing in Saudi Arabia

Outlook
Company expects continued progress on regulatory submissions and international commercialization initiatives
Co-Diagnostics anticipates further development of its product pipeline and manufacturing capabilities

Result Drivers
PRODUCT REVENUE - Co said Q2 revenue increase was primarily driven by higher product revenue
OPERATING EXPENSES - Lower general and administrative and R&D expenses reduced overall operating costs
REGULATORY AND COMMERCIAL MILESTONES - Advanced FDA submission, expanded manufacturing in Saudi Arabia, and initiated commercialization efforts in Latin America and India

Company press release: ID:nPn190mSXa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$170,000
$166,500 (2 Analysts)
Q2 Loss Per Share
 
$1.46
 
Q2 Net Loss
 
$6.30 mln
 
Q2 Adjusted EBITDA
 
-$5.80 mln
 
Q2 Operating Expenses
 
$6.30 mln
 
Q2 Operating Income
 
-$6.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Reuters Recommended Reads
Aug 12 - Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Aug 13 - Canada's Microbix Q3 revenue rises on higher antigen, QAPs sales
Aug 13 - Singapore's AsiaMedic HY loss narrows sharply on diagnostic imaging growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)